Vincristine as salvage treatment for refractory thrombotic thrombocytopenic purpura

被引：37

作者：

Ferrara, F ^{[1
]}

Copia, C ^{[1
]}

Annunziata, M ^{[1
]}

Spasiano, A ^{[1
]}

Di Grazia, C ^{[1
]}

Palmieri, S ^{[1
]}

Prossomariti, L ^{[1
]}

Mele, G ^{[1
]}

机构：

[1] Cardarelli Gen Hosp, Div Hematol, Naples, Italy

来源：

ANNALS OF HEMATOLOGY | 1999年 / 78卷 / 11期

关键词：

refractory thrombotic thrombocytopenic purpura vincristine;

D O I：

10.1007/s002770050549

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Vincristine (1.4 mg/m(2) on day 1, followed by 1 mg on days 4 and 7) was given to eight patients with thrombotic thrombocytopenic purpura (TTP) who were refractory to plasma exchange (n = 4) or plasma infusion (n = 4). Seven of eight patients (87%) achieved a complete response; one was refractory to treatment and died within a few weeks. After a median follow-up of 50 months, all responding patients are alive and well. Two patients relapsed and were successfully retreated with vincristine. Toxicity was mild, consisting of two episodes of leukopenia and one of autonomic neuropathy leading to paralytic ileus in a patient aged 70 years. We conclude that vincristine is highly effective in the treatment of patients suffering from refractory TTP, with negligible toxicity.

引用

页码：521 / 523

页数：3

共 13 条

[1]

BOBBIOPALLAVICINI E, 1994, EUR J HAEMATOL, V52, P222

[2] Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome [J].